Evidences include decreased NO synthase expression and abnormally high arginase enzyme levels in lungs of PAH patients, as well as overexpression of phosphodiesterase type 5 enzyme (PDE5), therefore reduced cyclic guanosine monophosphate (cGMP) levels [9,10]. Here, PDE5A is linked to pulmonary arterial hypertension.